{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2023_00029083", "CSN": null, "TRF": "ORD_1620416_01", "MRN": "48576961", "PhysicianId": "109266", "NPI": null}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1315068", "clinicalId": "1316415", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1620416_01", "SampleName": "US1546514.01", "Version": "0", "Sample": {"FM_Id": "ORD_1620416_01", "SampleId": "US1546514.01", "BlockId": "S112-04080F ", "TRFNumber": "ORD_1620416_01", "TestType": "FoundationOne CDx             ", "SpecFormat": "FFPE", "ReceivedDate": "2023_05_01", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}]}, "TumorPurity": "40", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "M112-10098", "MRN": "48576961", "FullName": "\u9673\u79c0\u537f", "FirstName": "Hsiu Ching", "LastName": "Chen", "SubmittedDiagnosis": "Pancreas ductal adenocarcinoma", "Gender": "Male", "DOB": "1950_03_01", "OrderingMD": "\u8a31\u52ad\u69ae", "OrderingMDId": "109266", "Pathologist": "\u738b\u857e\u742a", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Pancreas", "CollDate": "2023_02_04", "ReceivedDate": "2023-05-11 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Pancreatic Cancer"}, "PertinentNegatives": {"PertinentNegative": [{"Gene": "BRCA1"}, {"Gene": "BRCA2"}]}, "Summaries": {"alterationCount": "21", "clinicalTrialCount": "14", "resistiveCount": "0", "sensitizingCount": "0"}, "VariantProperties": {"VariantProperty": [{"geneName": "ABL1", "isVUS": "true", "variantName": "V824M"}, {"geneName": "AR", "isVUS": "true", "variantName": "S176R"}, {"geneName": "ATRX", "isVUS": "true", "variantName": "E2012V"}, {"geneName": "CARD11", "isVUS": "true", "variantName": "T670M"}, {"geneName": "CSF3R", "isVUS": "true", "variantName": "E450*"}, {"geneName": "ERBB3", "isVUS": "true", "variantName": "R488Q"}, {"geneName": "FH", "isVUS": "true", "variantName": "M266T"}, {"geneName": "HSD3B1", "isVUS": "true", "variantName": "amplification"}, {"geneName": "MAP2K4", "isVUS": "true", "variantName": "D186G"}, {"geneName": "NFE2L2", "isVUS": "true", "variantName": "I28_D29insEDI"}, {"geneName": "PDGFRA", "isVUS": "true", "variantName": "E34G"}, {"geneName": "PTCH1", "isVUS": "true", "variantName": "E44G"}, {"geneName": "SGK1", "isVUS": "true", "variantName": "E392Q"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "ARID1A", "Include": "true", "Alterations": {"Alteration": {"Name": "R376fs*15", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "13.04", "isEquivocal": "false", "name": "R376fs*15"}}, "Interpretation": "ARID1A encodes the AT_rich interactive domain_containing protein 1A, also known as Baf250a, a member of the SWI/SNF chromatin remodeling complex. Mutation, loss, or inactivation of ARID1A has been reported in many cancers, and the gene is considered a tumor suppressor (Guan et al., 2011; 21900401, Jones et al., 2012; 22009941, Wiegand et al., 2010; 20942669, Jones et al., 2010; 20826764, Yan et al., 2014; 24293408, Wang et al., 2012; 22808142, Huang et al., 2012; 22922871, Chan_On et al., 2013; 24185513, Mamo et al., 2012; 21892209). ARID1A mutations, which are mostly truncating, have been identified along the entire gene and often correlate with ARID1A protein loss (Jones et al., 2012; 22009941, Wiegand et al., 2010; 20942669, Jones et al., 2010; 20826764, Zang et al., 2012; 22484628, Wang et al., 2011; 22037554), whereas ARID1A missense mutations are mostly uncharacterized. ARID1A alterations are particularly prevalent in ovarian clear cell carcinoma (46_50%), ovarian and uterine endometrioid carcinomas (24_44%), and cholangiocarcinoma (27%); they are also reported in up to 27% of gastric carcinoma, esophageal adenocarcinoma, Waldenstrom macroglobulinemia, pediatric Burkitt lymphoma, hepatocellular carcinoma, colorectal carcinoma, and urothelial carcinoma samples analyzed (COSMIC, cBioPortal, 2023) (Tate et al., 2019; 30371878, Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210, Wu et al., 2014; 24618703, Jones et al., 2012; 22009941, Dulak et al., 2013; 23525077, Streppel et al., 2013; 23318448, Jiao et al., 2014; 24293293, Ross et al., 2014; 24563076). ARID1A loss is associated with microsatellite instability in ovarian and endometrial endometrioid adenocarcinomas (Huang et al., 2014; 25195947, Hussein et al., 2014; 25394778, Bosse et al., 2013; 23702729, Allo et al., 2014; 23887303, Okamura et al., 2020; 32111729), CRC (Chou et al., 2014; 24925223, Ye et al., 2014; 25311944, Wei et al., 2014; 25561809, Okamura et al., 2020; 32111729), and gastric cancer (Chen et al., 2015; 25583476, Wang et al., 2011; 22037554, Abe et al., 2012; 22915242, Wang et al., 2012; 22808142, Wiegand et al., 2014; 24767857, Okamura et al., 2020; 32111729). ARID1A protein loss is associated with tumors of poor histological grade for many tumor types, including colorectal cancer (CRC) (Chou et al., 2014; 24925223, Ye et al., 2014; 25311944, Wei et al., 2014; 25561809), cervical cancer (Katagiri et al., 2012; 22274316, Cho et al., 2013; 23427874), gastric cancer (Chen et al., 2015; 25583476, Wang et al., 2011; 22037554, Abe et al., 2012; 22915242, Wang et al., 2012; 22808142, Wiegand et al., 2014; 24767857), urothelial carcinoma (Gui et al., 2011; 21822268, Balbas_Martinez et al., 2013; 23650517, Faraj et al., 2014; 25175170), ovarian and endometrial cancers (Rahman et al., 2013; 22939958, Maeda et al., 2010; 21614196, Lowery et al., 2012; 22193641, Fadare et al., 2013; 23524907, Mao et al., 2013; 24076775, Katagiri et al., 2012; 22101352, Huang et al., 2014; 25195947, Hussein et al., 2014; 25394778, Bosse et al., 2013; 23702729, Allo et al., 2014; 23887303), breast carcinoma (Zhang et al., 2012; 21889920, Mamo et al., 2012; 21892209, Zhao et al., 2014; 24430365), and clear cell renal cell carcinoma (Lichner et al., 2013; 23416164); ARID1A mutation has been associated with poor outcomes for patients with cholangiocarcinoma (Feng et al., 2021; 33387086, Conci et al., 2020; 32020551, Simbolo et al., 2018; 29740198, Ruzzenente et al., 2016; 26717940). However, prognostic data regarding patient survival are often mixed and conflicting. There are no therapies approved to address the mutation or loss of ARID1A in cancer. However, on the basis of limited clinical and preclinical evidence, ARID1A inactivating mutations may lead to sensitivity to ATR inhibitors such as M6620 and ceralasertib (Williamson et al., 2016; 27958275). In a Phase 2 study of ceralasertib in solid tumors, 2 patients with endometrial carcinoma in the cohort with loss of ARID1A expression achieved CRs on ceralasertib monotherapy; at least 1 of these 2 patients carried an inactivating ARID1A mutation. In contrast, no responses were observed for patients with normal ARID1A expression treated with ceralasertib combined with olaparib (Aggarwal et al., 2021; ESMO Abstract 512O). One patient with small cell lung cancer harboring an ARID1A mutation experienced a PR when treated with M6620 combined with topotecan (Thomas et al., 2018; 29252124). In a Phase 1 trial, a patient with metastatic colorectal cancer (CRC) harboring both an ARID1A mutation and ATM loss treated with single_agent M6620 achieved a CR that was ongoing at 29 months (Yap et al., 2020; 32568634). On the basis of limited clinical and preclinical evidence, ARID1A inactivation may predict sensitivity to EZH2 inhibitors (Papadopoulos et al., 2022; ENA Abstract 188, Bitler et al., 2015; 25686104, Kim et al., 2015; 26552009). A Phase 1 study of EZH2 inhibitor CPI_0209 reported 1 PR for a patient with ARID1A_mutated endometrial cancer (Papadopoulos et al., 2022; ENA Abstract 188). Other studies have reported that the loss of ARID1A may activate the PI3K_AKT pathway and be linked with sensitivity to inhibitors of this pathway (Wiegand et al., 2014; 24559118, Huang et al., 2014; 24336158, Samartzis et al., 2014; 24979463). Patients with ARID1A alterations in advanced or metastatic solid tumors may derive benefit from treatment with anti_PD_1 or anti_PD_L1 immunotherapy (Okamura et al., 2020; 32111729). Loss of ARID1A expression has been associated with chemoresistance to platinum_based therapy for patients with ovarian clear cell carcinoma (Yokoyama et al., 2014; 24459582, Katagiri et al., 2012; 22101352) and to 5_fluorouracil in CRC cell lines (Xie et al., 2014; 24833095).", "Include": "true", "ClinicalTrialNote": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT02264678", "Include": "true"}, {"nctId": "NCT04802174", "Include": "true"}, {"nctId": "NCT04657068", "Include": "true"}, {"nctId": "NCT04514497", "Include": "true"}, {"nctId": "NCT03669601", "Include": "true"}, {"nctId": "NCT04616534", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "KRAS", "Include": "true", "Alterations": {"Alteration": {"Name": "G12V", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "22.84", "isEquivocal": "false", "name": "G12V"}}, "Interpretation": "KRAS encodes a member of the RAS family of small GTPases. Activating mutations in RAS genes can cause uncontrolled cell proliferation and tumor formation (Pylayeva_Gupta et al., 2011; 21993244, Kahn et al., 1987; 3310850). KRAS alterations affecting amino acids G12, G13, Q22, P34, A59, Q61, and A146, as well as mutations G10_A11insG, G10_A11insAG (also reported as G10_A11dup and G12_G13insAG), A18D, L19F, D33E, G60_A66dup/E62_A66dup, E62K, E63K, R68S, K117R, and K117N have been characterized as activating and oncogenic (Akagi et al., 2007; 17150185, Bollag et al., 1996; 8955068, Buhrman et al., 2010; 20194776, Colicelli, 2004; 15367757, Edkins et al., 2006; 16969076, Feig and Cooper, 1988; 3043178, Gremer et al., 2011; 20949621, Janakiraman et al., 2010; 20570890, Kim et al., 2016; 27147599, Lukman et al., 2010; 20838576, Naguib et al., 2011; 21371307, Prior et al., 2012; 22589270, Priv\u00e9 et al., 1992; 1565661, Pylayeva_Gupta et al., 2011; 21993244, Scheffzek et al., 1997; 9219684, Scholl et al., 2009; 19490892, Smith et al., 2010; 20147967, Tyner et al., 2009; 19075190, Valencia et al., 1991; 2029511, White et al., 2016; 26854029, Wiest et al., 1994; 8058307, Kim et al., 2016; 27147599, Angeles et al., 2019; 31289513, Tong et al., 2014; 24642870, Loree et al., 2021; 34117033). KRAS mutations have been observed in 91_95% of pancreatic ductal adenocarcinoma cases (cBio_Biankin et al., 2012; 23103869, cBio_Witkiewicz et al., 2015; 25855536), with the majority of mutations found at codon 12 (Feldmann et al., 2007; 17520196, Rachakonda et al., 2013; 23565280, Hruban et al., 1993; 8342602, Maitra et al., 2006; 16549325). KRAS mutations, particularly G12D, have been associated with decreased median survival time in patients with pancreatic ductal adenocarcinoma (Rachakonda et al., 2013; 23565280). Preclinical evidence suggests that KRAS activation may predict sensitivity to MEK inhibitors, such as trametinib, binimetinib, cobimetinib, and selumetinib (Nakano et al., 1984; 6320174, Pylayeva_Gupta et al., 2011; 21993244, Yamaguchi et al., 2011; 21523318, Watanabe et al., 2013; 23438367, Gilmartin et al., 2011; 21245089, Yeh et al., 2009; 19372556). For patients with pancreatic cancer, MEK inhibitor combinations are under investigation. A Phase 2 study of trametinib with pembrolizumab versus gemcitabine after stereotactic body radiotherapy (SBRT) reported increased median OS (mOS, 14.9 months vs. 12.8 months, HR=0.69) benefit for patients with KRAS_mutated, PD_L1 positive disease (Zhu et al., 2022; 35240087). Combination MEK/autophagy inhibitors are also under investigation based on preclinical evidence of increased autophagy downstream of KRAS_mutated pancreatic tumors (Kinsey et al., 2019; 30833748, Bryant et al., 2019; 30833752). A heavily pretreated patient with pancreatic cancer treated with trametinib plus hydroxychloroquine experienced a PR (Kinsey et al., 2019; 30833748). A Phase 2 study of the reoviral agent pelareorep with gemcitabine for patients with pancreatic cancer reported 1 PR, 23 SDs, and 5 PDs for 34 patients with a favorable median OS of 10.2 months (Mahalingam et al., 2018; 29799479). A Phase 1b study of second_line pelareorep with pembrolizumab and chemotherapy reported 1 PR of 17.4 months and a DCR of 30% (3/10) (Mahalingham et al., 2020;31694832); an earlier study reported no benefit from pelareorep in combination with paclitaxel/carboplatin (Noonan et al., 2016; 27039845). Trials combining MEK inhibitors with other targeted therapies, such as EGFR inhibitors (Ko et al., 2016; 26251290) or PI3K_AKT pathway inhibitors (LoRusso et al., 2012; ASCO Abstract 2566, Juric et al., 2014; ASCO Abstract 9051, Chung et al., 2017; 27978579, Bedard et al., 2015; 25500057), reported no PRs and frequent adverse events for patients with KRAS_mutated pancreatic cancer. Clinical trials combining various MEK inhibitors with gemcitabine reported no additional benefit compared to gemcitabine alone irrespective of KRAS mutation status (Van Laethem et al., 2017; 27975152, Infante et al., 2013; 23583440, Infante et al., 2014; 24915778, Van Cutsem et al., 2018; 29756206), despite promising results in earlier trials of MEK inhibitor monotherapies (Bodoky et al., 2012; 21594619, Rosen et al., 2008; ASCO Abstract 14585, Rinehart et al., 2004; 15483017, LoRusso et al., 2005; 16009947, Bodoky et al., 2012; 21594619, Infante et al., 2012; 22805291, Weekes et al., 2013; 23434733, Rinehart et al., 2004; 15483017, Infante et al., 2012; 22805291, Garrido_Laguna et al., 2015; 25897431). In a Phase 1 study evaluating the MEK_pan_RAF dual inhibitor CH5126766, 6 patients harboring KRAS mutations experienced PRs, including 3 with non_small cell lung cancer (NCSLC), 1 with low_grade serous ovarian carcinoma (LGSOC), 1 with endometrial adenocarcinoma, and 1 with multiple myeloma (Guo et al., 2020; 33128873). Combination of CH5126766 with the FAK inhibitor defactinib elicited PR rates of 50% (4/8) for patients with KRAS_mutated LGSOC and 12% (2/17) for patients with KRAS_mutated NSCLC in a Phase 1 study (Krebs et al., 2021; AACR Abstract CT019, Shinde et al., 2020; AACR Abstract CT143). Preclinical and clinical data suggest that KRAS mutations may predict clinical benefit from SHP2 inhibitors (Lu et al., 2019; 31068384, Mainardi et al., 2018; 29808006, Koczywas et al., 2021; AACR Abstract LB001, Brana et al., 2021; ASCO Abstract 3005, Bendell et al., 2020; EORTC_NCI_AACR Abstract 5). A Phase 1 study of RMC_4630 for relapsed/refractory solid tumors reported a DCR of 58% (23/40) for patients with NSCLC and KRAS mutations and a DCR of 75% (12/16) for patients with NSCLC and KRAS G12C mutations (Koczywas et al., 2021; AACR Abstract LB001). Interim results from a Phase 1/2 study of RMC_4630 plus cobimetinib reported tumor reduction in 3 of 8 patients with KRAS_mutated colorectal cancer (Bendell et al., 2020; EORTC_NCI_AACR Abstract 5). Preclinical studies suggest that KRAS activating mutations may confer sensitivity to SOS1 inhibitors such as BI_3406, MRTX0902, BI_1701963, and BAY_293 as single agents (Hofmann et al., 2021; 32816843, He et al., 2022; 36173339, Zhang et al., 2022; 36384290, Liu et al., 2023; 36793426, Ramharter et al., 2021; 33719426, Ketcham et al., 2022; 35833726) or in combination with covalent KRAS G12C inhibitors (Ketcham et al., 2022; 35833726, Haling et al., 2022; AACR Abstract ND02, Savarese et al., 2021; AACR Abstract 1271) and MEK inhibitors (Haling et al., 2022; AACR Abstract ND02, Norgard et al., 2022 AACR Tumor Immunology and Immunotherapy Abstract B23, Hofmann et al., 2022; AACR Abstract 3255, Plangger et al., 2022; 36048281, Ma et al., 2022; 36139627).", "Include": "true", "ClinicalTrialNote": "Multiple clinical studies have reported lack of efficacy of MEK inhibitors as monotherapy for treatment of KRAS_mutant pancreatic cancer. Emerging data suggest patients with KRAS_mutant pancreatic cancer may be sensitive to MEK_pan_RAF dual inhibitors or combination MEK/autophagy inhibitors. Preclinical evidence suggests that KRAS activating mutations may predict sensitivity to SOS1 inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT05669482", "Include": "true"}, {"nctId": "NCT04892017", "Include": "true"}, {"nctId": "NCT03825289", "Include": "true"}, {"nctId": "NCT04132505", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "PDGFRB", "Include": "true", "Alterations": {"Alteration": {"Name": "V823I", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "50.61", "isEquivocal": "false", "name": "V823I"}}, "Interpretation": "PDGFRB (Platelet_derived growth factor receptor, beta) encodes PDGFR_beta, a receptor tyrosine kinase that binds growth factors of the platelet_derived growth factor (PDGF) family. It is located on chromosome 5q33, and rearrangements involving this gene that result in its constitutive activation have been found in chronic myeloproliferative diseases (Apperley et al., 2002; 12181402, Roberts et al., 2012; 22897847, Chmielecki et al., 2012; 21938754, Vizmanos et al., 2004; 15087377, Kobayashi et al., 2014; 24628626). Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance. PDGFRB amplification was reported in 3% of samples in a study of pancreatic ductal adenocarcinoma (cBio_Witkiewicz et al., 2015; 25855536). However, active (phosphorylated) PDGFR_beta was reported in 93.5% (29/31) of pancreatic carcinoma samples in another study (Hwang et al., 2003; 14695158). PDGFRB mutations have been found in up to 1.1% of pancreatic adenocarcinoma cases (cBioPortal, COSMIC, Nov 2021)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210, Tate et al., 2019; 30371878). High expression of PDGFR_beta has been reported to be associated with worse metastasis_free and postoperative survival of patients with pancreatic cancer (Weissmueller et al., 2014; 24725405, Kurahara et al., 2016; 26940582). On the basis of clinical benefit for patients with renal cell carcinoma (Ornstein et al., 2015; ASCO GU Abstract 450)(Dornbusch et al., 2013; 24086736, Garcia_Donas et al., 2013; 23788753, Ma et al., 2016; 27488093) or solitary fibrous tumor (Stacchiotti et al., 2010; 20457621, Stacchiotti et al., 2012; 22711763), as well as for a patient with urothelial carcinoma (Shah et al., 2013; 23542751) and a patient with clear cell sarcoma (Stacchiotti et al., 2010; 20093352), PDGFRB expression is associated with sensitivity to sorafenib and sunitinib. PDGFRB fusions in myeloid neoplasms have been shown to be exquisitely sensitive to PDGFR_targeting therapies (Jawhar et al., 2017; 28725989, Appiah_Kubi et al., 2017; 28010895). Significant clinical benefit has also been achieved with dasatinib or imatinib in PDGFRB fusion_positive acute lymphoblastic leukemia (Kobayashi et al., 2015; 25400122, Lengline et al., 2013; 24186319, Roberts et al., 2014; 25207766, Weston et al., 2013; 23835704), chronic eosinophilic leukemia (Chang et al., 2016; DOI 10.1016/j.jcrpr.2015.10.003)( Li et al., 2011; 21072821, Metzgeroth et al., 2008; 18950453), and various other hematologic malignancies (Apperley et al., 2002; 12181402, Cornfield et al., 2012; 22331939, David et al., 2007; 16960151, Walz et al., 2007; 17296564, Winkelmann et al., 2013; 23186533). It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true", "ClinicalTrialNote": "PDGFRB amplification or activating mutations may predict sensitivity to certain PDGFRB_targeted therapies. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT02693535", "Include": "true"}, {"nctId": "NCT03297606", "Include": "true"}, {"nctId": "NCT04817956", "Include": "true"}, {"nctId": "NCT01738139", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "CDKN2A/B", "Include": "true", "Alterations": {"Alteration": [{"Name": "CDKN2B loss", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "CDKN2B loss"}}, "Interpretation": "CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor p15INK4b (Quelle et al., 1995; 8521522, Sharpless, 2005; 15878778). Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby maintaining the growth_suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6_cyclin_Rb pathway and loss of cell cycle control (Gazzeri et al., 1998; 9484839, Roussel, 1999; 10498883). The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition (Sherr et al., 2005; 16869746, Ozenne et al., 2010; 20549699). One or more alterations observed here are predicted to result in p16INK4a loss of function (Ruas et al., 1999; 10498896, Jones et al., 2007; 17909018, Haferkamp et al., 2008; 18843795, Huot et al., 2002; 12417717, Rizos et al., 2001; 11518711, Gombart et al., 1997; 9324288, Yang et al., 1995; 7780957, Parry and Peters, 1996; 8668202, Greenblatt et al., 2003; 12606942, Yarbrough et al., 1999; 10491434, Poi et al., 2001; 11255261, Byeon et al., 1998; 9660926, Kannengiesser et al., 2009; 19260062, Lal et al., 2000; 10719365, Koh et al., 1995; 7777061, McKenzie et al., 2010; 20340136, Miller et al., 2011; 21462282, Arap et al., 1997; 905385, Scaini et al., 2014; 24659262, Jenkins et al., 2013; 23190892, Walker et al., 1999; 10389768, Rutter et al., 2003; 12853981). One or more alterations seen here are predicted to result in p14ARF loss of function (Rizos et al., 2001; 11518711, Itahana and Zhang, 2008; 18538737, Zhang and Xiong, 1999; 10360174, Zhang et al., 1998; 9529249, Rutter et al., 2003; 12853981). CDKN2B alterations such as seen here are predicted to inactivate p15INK4b (Jafri et al., 2015; 25873077). CDKN2A/B loss has been reported in 36% of pancreatic ductal carcinomas (Witkiewicz et al., 2015; 25855536). CDKN2A loss has been reported in 25_100% of pancreatic ductal adenocarcinomas analyzed, with a portion of those due to gene deletion (Tsiambas et al., 2007; 17600882, Bergmann et al., 2006; 16497872, Attri et al., 2005; 15985168, Rachakonda et al., 2013; 23565280). A study of multiple pancreatic cancer subtypes reported no CDKN2A mutations (0/6 samples) and loss of heterozygosity in only one of four samples of pancreatic acinar carcinomas, compared to mutation or loss of heterozygosity in 38% and 67% of pancreatic ductal carcinomas, respectively (Moore et al., 2001; 11161385). Promoter methylation affecting p16INK4a and p14ARF has been reported in 43% (16/37) and 20.6% (7/34), respectively, of pancreatic fluid specimens of patients with pancreatic carcinoma (Klump et al., 2003; 12610506). The loss or decrease of p16INK4a expression levels in pancreatic ductal adenocarcinoma has been reported in 32_80% of samples analyzed and one study reported concurrent loss of p16INK4a and p14ARF protein expression in 68% (19/28) of cases (Oshima et al., 2013; 23470568, Tsiambas et al., 2007; 17600882, Geradts et al., 2001; 11706079). p16INK4a expression has been associated with improved OS in pancreatic adenocarcinoma patients in univariate and multivariate analysis (Chang et al., 2010; 20665497). Furthermore, CDKN2A alterations (deletion or mutation) in the presence of concomitant KRAS mutation may correlate with shorter survival in patients with pancreatic ductal adenocarcinoma (Oshima et al., 2013; 23470568). Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib (Konecny et al., 2011; 21278246, Katsumi et al., 2011; 21871868, Cen et al., 2012; 22711607, Logan et al., 2013; 23898052). Clinical data in mesothelioma, breast cancer, and uterine leiomyosarcoma indicate that CDKN2A loss may predict sensitivity to abemaciclib (Fennell et al., 2022; 35157829) and palbociclib treatment (Elvin et al., 2017; 28283584, Gao et al., 2015; 26715889). However, multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents (Gopalan et al., 2014; ASCO Abstract 8077, Peguero et al., 2016; ASCO Abstract 2528, Konecny et al., 2016; ASCO Abstract 5557)(DeMichele et al., 2014; 25501126, Finn et al., 2015; 25524798, Infante et al., 2016; 27542767, Johnson et al., 2014; 24797823); it is not known whether CDK4/6 inhibitors would be beneficial in this case. The p15INK4b protein encoded by CDKN2B is known to inhibit CDK4, and although concomitant loss of CDKN2A and CDKN2B may predict sensitivity to CDK4/6 inhibitors, such as ribociclib, abemaciclib, and palbociclib (Infante et al., 2014; ASCO Abstract 2528, Shapiro et al., 2013; ASCO Abstract 2500, Flaherty et al., 2012; 22090362, Dickson et al., 2013; 23569312, Finn et al., 2015; 25524798, DeMichele et al., 2014; 25501126), direct supporting data for CDKN2B alteration as a predictive biomarker for these therapies are limited (Su et al., 2019; 31700061, Tramontana et al., 2020; 32923894). Although preclinical studies have suggested that loss of p14ARF function may be associated with reduced sensitivity to MDM2 inhibitors (Van Maerken et al., 2011; 21460101, Gamble et al., 2012; 21725357), the clinical relevance of p14ARF as a predictive biomarker is not clear. Germline CDKN2A mutation is associated with melanoma_pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer (Whelan et al., 1995; 7666917). Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma (Hansson, 2010; 20687502, Hogg et al., 1998; 9479083). CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases (De Unamuno et al., 2018; 29543703, Soura et al., 2016; 26892650, Huerta et al., 2018; 29405243). CDKN2A alteration has also been implicated in familial melanoma_astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors (Kaufman et al., 1993; 8414022, Bahuau et al., 1998; 9622062, Chan et al., 2017; 28699883). In the appropriate clinical context, germline testing of CDKN2A is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}, {"Name": "CDKN2A loss", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "CDKN2A loss"}}, "Interpretation": "CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor p15INK4b (Quelle et al., 1995; 8521522, Sharpless, 2005; 15878778). Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby maintaining the growth_suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6_cyclin_Rb pathway and loss of cell cycle control (Gazzeri et al., 1998; 9484839, Roussel, 1999; 10498883). The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition (Sherr et al., 2005; 16869746, Ozenne et al., 2010; 20549699). One or more alterations observed here are predicted to result in p16INK4a loss of function (Ruas et al., 1999; 10498896, Jones et al., 2007; 17909018, Haferkamp et al., 2008; 18843795, Huot et al., 2002; 12417717, Rizos et al., 2001; 11518711, Gombart et al., 1997; 9324288, Yang et al., 1995; 7780957, Parry and Peters, 1996; 8668202, Greenblatt et al., 2003; 12606942, Yarbrough et al., 1999; 10491434, Poi et al., 2001; 11255261, Byeon et al., 1998; 9660926, Kannengiesser et al., 2009; 19260062, Lal et al., 2000; 10719365, Koh et al., 1995; 7777061, McKenzie et al., 2010; 20340136, Miller et al., 2011; 21462282, Arap et al., 1997; 905385, Scaini et al., 2014; 24659262, Jenkins et al., 2013; 23190892, Walker et al., 1999; 10389768, Rutter et al., 2003; 12853981). One or more alterations seen here are predicted to result in p14ARF loss of function (Rizos et al., 2001; 11518711, Itahana and Zhang, 2008; 18538737, Zhang and Xiong, 1999; 10360174, Zhang et al., 1998; 9529249, Rutter et al., 2003; 12853981). CDKN2B alterations such as seen here are predicted to inactivate p15INK4b (Jafri et al., 2015; 25873077). CDKN2A/B loss has been reported in 36% of pancreatic ductal carcinomas (Witkiewicz et al., 2015; 25855536). CDKN2A loss has been reported in 25_100% of pancreatic ductal adenocarcinomas analyzed, with a portion of those due to gene deletion (Tsiambas et al., 2007; 17600882, Bergmann et al., 2006; 16497872, Attri et al., 2005; 15985168, Rachakonda et al., 2013; 23565280). A study of multiple pancreatic cancer subtypes reported no CDKN2A mutations (0/6 samples) and loss of heterozygosity in only one of four samples of pancreatic acinar carcinomas, compared to mutation or loss of heterozygosity in 38% and 67% of pancreatic ductal carcinomas, respectively (Moore et al., 2001; 11161385). Promoter methylation affecting p16INK4a and p14ARF has been reported in 43% (16/37) and 20.6% (7/34), respectively, of pancreatic fluid specimens of patients with pancreatic carcinoma (Klump et al., 2003; 12610506). The loss or decrease of p16INK4a expression levels in pancreatic ductal adenocarcinoma has been reported in 32_80% of samples analyzed and one study reported concurrent loss of p16INK4a and p14ARF protein expression in 68% (19/28) of cases (Oshima et al., 2013; 23470568, Tsiambas et al., 2007; 17600882, Geradts et al., 2001; 11706079). p16INK4a expression has been associated with improved OS in pancreatic adenocarcinoma patients in univariate and multivariate analysis (Chang et al., 2010; 20665497). Furthermore, CDKN2A alterations (deletion or mutation) in the presence of concomitant KRAS mutation may correlate with shorter survival in patients with pancreatic ductal adenocarcinoma (Oshima et al., 2013; 23470568). Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib (Konecny et al., 2011; 21278246, Katsumi et al., 2011; 21871868, Cen et al., 2012; 22711607, Logan et al., 2013; 23898052). Clinical data in mesothelioma, breast cancer, and uterine leiomyosarcoma indicate that CDKN2A loss may predict sensitivity to abemaciclib (Fennell et al., 2022; 35157829) and palbociclib treatment (Elvin et al., 2017; 28283584, Gao et al., 2015; 26715889). However, multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents (Gopalan et al., 2014; ASCO Abstract 8077, Peguero et al., 2016; ASCO Abstract 2528, Konecny et al., 2016; ASCO Abstract 5557)(DeMichele et al., 2014; 25501126, Finn et al., 2015; 25524798, Infante et al., 2016; 27542767, Johnson et al., 2014; 24797823); it is not known whether CDK4/6 inhibitors would be beneficial in this case. The p15INK4b protein encoded by CDKN2B is known to inhibit CDK4, and although concomitant loss of CDKN2A and CDKN2B may predict sensitivity to CDK4/6 inhibitors, such as ribociclib, abemaciclib, and palbociclib (Infante et al., 2014; ASCO Abstract 2528, Shapiro et al., 2013; ASCO Abstract 2500, Flaherty et al., 2012; 22090362, Dickson et al., 2013; 23569312, Finn et al., 2015; 25524798, DeMichele et al., 2014; 25501126), direct supporting data for CDKN2B alteration as a predictive biomarker for these therapies are limited (Su et al., 2019; 31700061, Tramontana et al., 2020; 32923894). Although preclinical studies have suggested that loss of p14ARF function may be associated with reduced sensitivity to MDM2 inhibitors (Van Maerken et al., 2011; 21460101, Gamble et al., 2012; 21725357), the clinical relevance of p14ARF as a predictive biomarker is not clear. Germline CDKN2A mutation is associated with melanoma_pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer (Whelan et al., 1995; 7666917). Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma (Hansson, 2010; 20687502, Hogg et al., 1998; 9479083). CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases (De Unamuno et al., 2018; 29543703, Soura et al., 2016; 26892650, Huerta et al., 2018; 29405243). CDKN2A alteration has also been implicated in familial melanoma_astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors (Kaufman et al., 1993; 8414022, Bahuau et al., 1998; 9622062, Chan et al., 2017; 28699883). In the appropriate clinical context, germline testing of CDKN2A is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}]}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSI is rare in pancreatic carcinoma, reported in less than 1% of samples (n=>1,000)(Hu et al., 2018; 29367431, Campbell et al., 2017; 29056344, Pihlak et al., 2018; 29329208, Salem et al., 2018; 29523759, Lahgi et al., 2012; 23029359). The prognostic significance of MSI in pancreatic cancer is unknown (PubMed, Aug 2022). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "TP53", "Include": "true", "Alterations": {"Alteration": {"Name": "R342*", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "26.7", "isEquivocal": "false", "name": "R342*"}}, "Interpretation": "Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers (Brown et al., 2009; 19935675). Alterations such as seen here may disrupt TP53 function or expression (Joerger and Fersht, 2008; 18410249, Kato et al., 2003; 12826609, Kamada et al., 2011; 20978130, Zerdoumi et al., 2017; 28472496, Yamada et al., 2007; 17690113). TP53 mutations have been reported in 33_75% of pancreatic carcinomas, with the majority occurring as missense mutations, while deletion of TP53 has been found in 66% of pancreatic ductal adenocarcinoma cases (cBio_Biankin et al., 2012; 23103869, Morton et al., 2010; 20018721, Scarpa et al., 1993; 8494051, Luo et al., 2013; 22782330). TP53 mutations are common in pancreatic ductal adenocarcinomas and are known to occur in the process of pancreatic carcinogenesis (Iacobuzio_Donahue et al., 2012; 22896692, Macgregor_Das and Iacobuzio_Donahue, 2013; 22806689). Additionally, aberrant expression of p53 has been found in 54_81% of pancreatic ductal adenocarcinoma cases (Oshima et al., 2013; 23470568, Ottenhof et al., 2012; 22351431, Tsiambas et al., 2010; 20414934, Scarpa et al., 1993; 8494051). Studies have found inconsistent results regarding the prognostic significance of p53 expression in pancreatic ductal adenocarcinoma, although one study correlated low levels of TP53 mRNA with poor patient prognosis (Ansari et al., 2011; 21644238, Oshima et al., 2013; 23470568, Grochola et al., 2011; 21404460). There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib (Hirai et al., 2010; 20107315, Bridges et al., 2011; 21799033, Rajeshkumar et al., 2011; 21389100, Osman et al., 2015; 25504633) or p53 gene therapy such as SGT53 (Xu et al., 2002; 12489850, Xu et al., 2001; 11713371, Camp et al., 2013; 23470564, Kim et al., 2015; 25240597, Pirollo et al., 2016; 27357628, Leung et al., 2021; ASCO Abstract 4139). In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype (Leijen et al., 2016; 27601554). A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR for patients with platinum_refractory TP53_mutated ovarian, Fallopian tube, or peritoneal cancer (Moore et al., 2019; ASCO Abstract 5513). A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR for patients with platinum_refractory TP53_mutated ovarian cancer (Leijen et al., 2016; 27998224). The combination of adavosertib with paclitaxel and carboplatin for patients with TP53_mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone (Oza et al., 2015; ASCO Abstract 5506). In the Phase 2 VIKTORY trial, patients with TP53_mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel (Lee et al., 2019; 31315834). A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations (Mendez et al., 2018; 29535125). The Phase 2 FOCUS4_C trial for patients with TP53_ and RAS_mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring (Seligmann et al., 2021; 34538072). In a Phase 1b clinical trial of SGT_53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage (Pirollo et al., 2016; 27357628). Missense mutations leading to TP53 inactivation may be sensitive to therapies that reactivate mutated p53 such as eprenetapopt. In a Phase 1b trial for patients with p53_positive high_grade serous ovarian cancer, eprenetapopt combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR (Gourley et al., 2016; ASCO Abstract 5571). A Phase 1 trial of eprenetapopt with pembrolizumab for patients with solid tumors reported an ORR of 10% (3/29) (Park et al., 2022; 36084396). One or more of the TP53 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with Li_Fraumeni syndrome (ClinVar, Sep 2022)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li_Fraumeni syndrome and the early onset of many cancers (Bougeard et al., 2015; 26014290, Sorrell et al., 2013; 23355100, Nichols et al., 2001; 11219776), including sarcomas (Kleihues et al., 1997; 9006316, Gonzalez et al., 2009; 19204208). Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000 (Lalloo et al., 2003; 12672316) to 1:20,000 (Gonzalez et al., 2009; 19204208). For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30 (Mandelker et al., 2019; 31050713). In the appropriate clinical context, germline testing of TP53 is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "06", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "06"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB level associated with lower rates of clinical benefit from treatment with PD_1_ or PD_L1_targeting immune checkpoint inhibitors compared with patients with tumors harboring higher TMB levels, based on several studies in multiple solid tumor types (Goodman et al., 2017; 28835386, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). Pancreatic carcinomas, including ductal and acinar subtypes, have been reported to harbor a median TMB of 2_3 mutations per megabase (muts/Mb), and 0_2% of cases have high TMB (>20 muts/Mb)(FMI_Chalmers et al., 2017; 28420421); TMB has not been assessed in pancreatic mucinous neoplasms (PubMed, Oct 2022). A study of patients with pancreatic ductal adenocarcinoma harboring mismatch repair gene mutations reported improved prognosis for patients with high TMB measured in tissue samples (defined as >50 mutations; survival 69_314 months) compared to those with lower TMB (average of 5.7 mutations; 10_42 months) (Hu et al., 2017; ASCO Abstract e15791). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple pan_tumor studies, increased tissue tumor mutational burden (TMB) was associated with sensitivity to immune checkpoint inhibitors (Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947, Ott et al., 2019; 30557521, Cristescu et al., 2022; 35101941, Friedman et al., 2022; 34876409, Sturgill et al., 2022; 35274716). In the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors, significant improvement in ORR was observed for patients with TMB \u226510 Muts/Mb (as measured by this assay) compared with those with TMB <10 Muts/Mb in a large cohort that included multiple tumor types (Marabelle et al., 2020; 32919526); similar findings were observed in the KEYNOTE 028 and 012 trials (Cristescu et al., 2018; 30309915). At the same TMB cutpoint, retrospective analysis of patients with solid tumors treated with any checkpoint inhibitor identified that tissue TMB scores \u2265 10 Muts/Mb were associated with prolonged time to treatment failure compared with scores <10 muts/Mb (HR=0.68) (Sturgill et al., 2022; 35274716). For patients with solid tumors treated with nivolumab plus ipilimumab in the CheckMate 848 trial, improved responses were observed in patients with a tissue TMB \u2265 10 Muts/Mb independent of blood TMB at any cutpoint in matched samples (Schenker at al., 2022; AACR Abstract 7845). However, support for higher TMB thresholds and efficacy was observed in the prospective Phase 2 MyPathway trial of atezolizumab for patients with pan_solid tumors, where improved ORR and DCR was seen in patients with TMB \u2265 16 Muts/Mb than those with TMB \u2265 10 and <16 Muts/Mb (Friedman et al., 2022; 34876409). Similarly, analyses across several solid tumor types reported that patients with higher TMB (defined as \u226516_20 Muts/Mb) achieved greater clinical benefit from PD_1 or PD_L1_targeting monotherapy compared with patients with higher TMB treated with chemotherapy (Legrand et al., 2018; ASCO Abstract 12000) or those with lower TMB treated with PD_1 or PD_L1_targeting agents (Goodman et al., 2017; 28835386).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "ARID1A", "Alteration": "R376fs*15", "Title": "Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents", "StudyPhase": "PHASE 1/2", "Target": "ATR, PARP, PD_L1", "Locations": "Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Goyang_si (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Coventry (United Kingdom), Sutton (United Kingdom), Oxford (United Kingdom)", "NCTID": "NCT02264678", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors.", "Include": "true"}, {"Gene": "ARID1A", "Alteration": "R376fs*15", "Title": "Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High_Grade Neuroendocrine Cancers", "StudyPhase": "PHASE 1/2", "Target": "ATR", "Locations": "Maryland", "NCTID": "NCT04802174", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors.", "Include": "true"}, {"Gene": "ARID1A", "Alteration": "R376fs*15", "Title": "A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "ATR", "Locations": "London (United Kingdom), Colorado, Oklahoma, Texas, Pennsylvania, Tennessee, Florida", "NCTID": "NCT04657068", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors.", "Include": "true"}, {"Gene": "ARID1A", "Alteration": "R376fs*15", "Title": "Testing the Addition of an Anti_cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer", "StudyPhase": "PHASE 1", "Target": "TOP1, ATR", "Locations": "California, Arizona, Minnesota, Oklahoma, Missouri, Pennsylvania, Connecticut, New York", "NCTID": "NCT04514497", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors.", "Include": "true"}, {"Gene": "ARID1A", "Alteration": "R376fs*15", "Title": "AZD6738 & Gemcitabine as Combination Therapy", "StudyPhase": "PHASE 1", "Target": "ATR", "Locations": "Cambridge (United Kingdom)", "NCTID": "NCT03669601", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors.", "Include": "true"}, {"Gene": "ARID1A", "Alteration": "R376fs*15", "Title": "Testing the Addition of an Anti_cancer Drug, BAY 1895344 ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors", "StudyPhase": "PHASE 1", "Target": "ATR", "Locations": "Massachusetts, Maryland", "NCTID": "NCT04616534", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "G12V", "Title": "Study of Avutometinib (VS_6766) +Defactinib With Gemcitabine and Nab_paclitaxel in Patients With Pancreatic Cancer", "StudyPhase": "PHASE 1/2", "Target": "RAFs, MEK, FAK", "Locations": "Missouri, New York", "NCTID": "NCT05669482", "Note": "Multiple clinical studies have reported lack of efficacy of MEK inhibitors as monotherapy for treatment of KRAS_mutant pancreatic cancer. Emerging data suggest patients with KRAS_mutant pancreatic cancer may be sensitive to MEK_pan_RAF dual inhibitors or combination MEK/autophagy inhibitors. Preclinical evidence suggests that KRAS activating mutations may predict sensitivity to SOS1 inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "G12V", "Title": "A Safety, Tolerability and PK Study of DCC_3116 in Patients With RAS or RAF Mutant Advanced or Metastatic Solid Tumors.", "StudyPhase": "PHASE 1/2", "Target": "ULK1, ULK2, MEK", "Locations": "Massachusetts, New York, Texas, Pennsylvania", "NCTID": "NCT04892017", "Note": "Multiple clinical studies have reported lack of efficacy of MEK inhibitors as monotherapy for treatment of KRAS_mutant pancreatic cancer. Emerging data suggest patients with KRAS_mutant pancreatic cancer may be sensitive to MEK_pan_RAF dual inhibitors or combination MEK/autophagy inhibitors. Preclinical evidence suggests that KRAS activating mutations may predict sensitivity to SOS1 inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "G12V", "Title": "Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer", "StudyPhase": "PHASE 1", "Target": "MEK", "Locations": "Utah", "NCTID": "NCT03825289", "Note": "Multiple clinical studies have reported lack of efficacy of MEK inhibitors as monotherapy for treatment of KRAS_mutant pancreatic cancer. Emerging data suggest patients with KRAS_mutant pancreatic cancer may be sensitive to MEK_pan_RAF dual inhibitors or combination MEK/autophagy inhibitors. Preclinical evidence suggests that KRAS activating mutations may predict sensitivity to SOS1 inhibitors.", "Include": "true"}, {"Gene": "KRAS", "Alteration": "G12V", "Title": "Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer", "StudyPhase": "PHASE 1", "Target": "MEK", "Locations": "Texas", "NCTID": "NCT04132505", "Note": "Multiple clinical studies have reported lack of efficacy of MEK inhibitors as monotherapy for treatment of KRAS_mutant pancreatic cancer. Emerging data suggest patients with KRAS_mutant pancreatic cancer may be sensitive to MEK_pan_RAF dual inhibitors or combination MEK/autophagy inhibitors. Preclinical evidence suggests that KRAS activating mutations may predict sensitivity to SOS1 inhibitors.", "Include": "true"}, {"Gene": "PDGFRB", "Alteration": "V823I", "Title": "TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer", "StudyPhase": "PHASE 2", "Target": "CDK4, CDK6, FLT3, VEGFRs, CSF1R, KIT, RET, mTOR, ERBB2, MEK, BRAF, PARP, PD_1, CTLA_4, PD_L1, TRKB, ALK, TRKC, ROS1, TRKA, FGFRs", "Locations": "Hawaii, Washington, Oregon, California", "NCTID": "NCT02693535", "Note": "PDGFRB amplification or activating mutations may predict sensitivity to certain PDGFRB_targeted therapies. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "PDGFRB", "Alteration": "V823I", "Title": "Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)", "StudyPhase": "PHASE 2", "Target": "VEGFRs, ABL, SRC, ALK, ROS1, AXL, TRKA, MET, TRKC, DDR2, KIT, EGFR, PD_1, CTLA_4, PARP, CDK4, CDK6, FLT3, CSF1R, RET, mTOR, ERBB2, MEK, BRAF, SMO", "Locations": "Vancouver (Canada), Kelowna (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), Ottawa (Canada), Montreal (Canada), Toronto (Canada), Kingston (Canada), London (Canada)", "NCTID": "NCT03297606", "Note": "PDGFRB amplification or activating mutations may predict sensitivity to certain PDGFRB_targeted therapies. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "PDGFRB", "Alteration": "V823I", "Title": "Improving Public Cancer Care by Implementing Precision Medicine in Norway", "StudyPhase": "PHASE 2", "Target": "PD_L1, VEGFA, ERBB2, ALK, RET, PARP, SMO, TRKB, TRKC, ROS1, TRKA, MEK, BRAF, PI3K_alpha, FGFR1, FGFR2, FGFR3, MET, KIT, ABL", "Locations": "Troms\u00f8 (Norway), Bod\u00f8 (Norway), Hamar (Norway), Oslo (Norway), Fredrikstad (Norway), Drammen (Norway), Trondheim (Norway), Skien (Norway), F\u00f8rde (Norway), Bergen (Norway)", "NCTID": "NCT04817956", "Note": "PDGFRB amplification or activating mutations may predict sensitivity to certain PDGFRB_targeted therapies. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}, {"Gene": "PDGFRB", "Alteration": "V823I", "Title": "Ipilimumab and Imatinib Mesylate in Advanced Cancer", "StudyPhase": "PHASE 1", "Target": "KIT, ABL, CTLA_4", "Locations": "Texas", "NCTID": "NCT01738139", "Note": "PDGFRB amplification or activating mutations may predict sensitivity to certain PDGFRB_targeted therapies. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "21900401", "FullCitation": "Guan B, et al. Cancer Res. (2011) pmid: 21900401", "Include": "true"}, {"number": "1", "ReferenceId": "22009941", "FullCitation": "Jones S, et al. Hum. Mutat. (2012) pmid: 22009941", "Include": "true"}, {"number": "2", "ReferenceId": "20942669", "FullCitation": "Wiegand KC, et al. N. Engl. J. Med. (2010) pmid: 20942669", "Include": "true"}, {"number": "3", "ReferenceId": "20826764", "FullCitation": "Jones S, et al. Science (2010) pmid: 20826764", "Include": "true"}, {"number": "4", "ReferenceId": "24293408", "FullCitation": "Yan HB, et al. Carcinogenesis (2014) pmid: 24293408", "Include": "true"}, {"number": "5", "ReferenceId": "22808142", "FullCitation": "Wang DD, et al. PLoS ONE (2012) pmid: 22808142", "Include": "true"}, {"number": "6", "ReferenceId": "22922871", "FullCitation": "Huang J, et al. Nat. Genet. (2012) pmid: 22922871", "Include": "true"}, {"number": "7", "ReferenceId": "24185513", "FullCitation": "Chan_On W, et al. Nat. Genet. (2013) pmid: 24185513", "Include": "true"}, {"number": "8", "ReferenceId": "21892209", "FullCitation": "Mamo A, et al. Oncogene (2012) pmid: 21892209", "Include": "true"}, {"number": "9", "ReferenceId": "22484628", "FullCitation": "Zang ZJ, et al. Nat. Genet. (2012) pmid: 22484628", "Include": "true"}, {"number": "10", "ReferenceId": "22037554", "FullCitation": "Wang K, et al. Nat. Genet. (2011) pmid: 22037554", "Include": "true"}, {"number": "11", "ReferenceId": "30371878", "FullCitation": "Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878", "Include": "true"}, {"number": "12", "ReferenceId": "22588877", "FullCitation": "Cerami E, et al. Cancer Discov (2012) pmid: 22588877", "Include": "true"}, {"number": "13", "ReferenceId": "23550210", "FullCitation": "Gao J, et al. Sci Signal (2013) pmid: 23550210", "Include": "true"}, {"number": "14", "ReferenceId": "24618703", "FullCitation": "Wu RC, et al. Cancer Biol. Ther. (2014) pmid: 24618703", "Include": "true"}, {"number": "15", "ReferenceId": "23525077", "FullCitation": "Dulak AM, et al. Nat. Genet. (2013) pmid: 23525077", "Include": "true"}, {"number": "16", "ReferenceId": "23318448", "FullCitation": "Streppel MM, et al. Oncogene (2014) pmid: 23318448", "Include": "true"}, {"number": "17", "ReferenceId": "24293293", "FullCitation": "Jiao Y, et al. J. Pathol. (2014) pmid: 24293293", "Include": "true"}, {"number": "18", "ReferenceId": "24563076", "FullCitation": "Ross JS, et al. Oncologist (2014) pmid: 24563076", "Include": "true"}, {"number": "19", "ReferenceId": "25195947", "FullCitation": "Huang HN, et al. Histopathology (2015) pmid: 25195947", "Include": "true"}, {"number": "20", "ReferenceId": "25394778", "FullCitation": "Hussein YR, et al. Mod. Pathol. (2015) pmid: 25394778", "Include": "true"}, {"number": "21", "ReferenceId": "23702729", "FullCitation": "Bosse T, et al. Mod. Pathol. (2013) pmid: 23702729", "Include": "true"}, {"number": "22", "ReferenceId": "23887303", "FullCitation": "Allo G, et al. Mod. Pathol. (2014) pmid: 23887303", "Include": "true"}, {"number": "23", "ReferenceId": "32111729", "FullCitation": "Okamura R, et al. J Immunother Cancer (2020) pmid: 32111729", "Include": "true"}, {"number": "24", "ReferenceId": "24925223", "FullCitation": "Chou A, et al. Hum. Pathol. (2014) pmid: 24925223", "Include": "true"}, {"number": "25", "ReferenceId": "25311944", "FullCitation": "Ye J, et al. Hum. Pathol. (2014) pmid: 25311944", "Include": "true"}, {"number": "26", "ReferenceId": "25561809", "FullCitation": "Wei XL, et al. World J. Gastroenterol. (2014) pmid: 25561809", "Include": "true"}, {"number": "27", "ReferenceId": "25583476", "FullCitation": "Chen K, et al. Proc. Natl. Acad. Sci. U.S.A. (2015) pmid: 25583476", "Include": "true"}, {"number": "28", "ReferenceId": "22915242", "FullCitation": "Abe H, et al. Virchows Arch. (2012) pmid: 22915242", "Include": "true"}, {"number": "29", "ReferenceId": "24767857", "FullCitation": "Wiegand KC, et al. Hum. Pathol. (2014) pmid: 24767857", "Include": "true"}, {"number": "30", "ReferenceId": "22274316", "FullCitation": "Katagiri A, et al. Int. J. Gynecol. Cancer (2012) pmid: 22274316", "Include": "true"}, {"number": "31", "ReferenceId": "23427874", "FullCitation": "Cho H, et al. Hum. Pathol. (2013) pmid: 23427874", "Include": "true"}, {"number": "32", "ReferenceId": "21822268", "FullCitation": "Gui Y, et al. Nat. Genet. (2011) pmid: 21822268", "Include": "true"}, {"number": "33", "ReferenceId": "23650517", "FullCitation": "Balb\u00e1s_Mart\u00ednez C, et al. PLoS ONE (2013) pmid: 23650517", "Include": "true"}, {"number": "34", "ReferenceId": "25175170", "FullCitation": "Faraj SF, et al. Hum. Pathol. (2014) pmid: 25175170", "Include": "true"}, {"number": "35", "ReferenceId": "22939958", "FullCitation": "Rahman M, et al. Hum. Pathol. (2013) pmid: 22939958", "Include": "true"}, {"number": "36", "ReferenceId": "21614196", "FullCitation": "Maeda D, et al. Int J Mol Sci (2010) pmid: 21614196", "Include": "true"}, {"number": "37", "ReferenceId": "22193641", "FullCitation": "Lowery WJ, et al. Int. J. Gynecol. Cancer (2012) pmid: 22193641", "Include": "true"}, {"number": "38", "ReferenceId": "23524907", "FullCitation": "Fadare O, et al. Mod. Pathol. (2013) pmid: 23524907", "Include": "true"}, {"number": "39", "ReferenceId": "24076775", "FullCitation": "Mao TL, et al. Am. J. Surg. Pathol. (2013) pmid: 24076775", "Include": "true"}, {"number": "40", "ReferenceId": "22101352", "FullCitation": "Katagiri A, et al. Mod. Pathol. (2012) pmid: 22101352", "Include": "true"}, {"number": "41", "ReferenceId": "21889920", "FullCitation": "Zhang X, et al. Cancer Epidemiol (2012) pmid: 21889920", "Include": "true"}, {"number": "42", "ReferenceId": "24430365", "FullCitation": "Zhao J, et al. Tumour Biol. (2014) pmid: 24430365", "Include": "true"}, {"number": "43", "ReferenceId": "23416164", "FullCitation": "Lichner Z, et al. Am. J. Pathol. (2013) pmid: 23416164", "Include": "true"}, {"number": "44", "ReferenceId": "33387086", "FullCitation": "Feng F, et al. Int J Clin Oncol (2021) pmid: 33387086", "Include": "true"}, {"number": "45", "ReferenceId": "32020551", "FullCitation": "Conci S, et al. Updates Surg (2020) pmid: 32020551", "Include": "true"}, {"number": "46", "ReferenceId": "29740198", "FullCitation": "Simbolo M, et al. Sci Rep (2018) pmid: 29740198", "Include": "true"}, {"number": "47", "ReferenceId": "26717940", "FullCitation": "Ruzzenente A, et al. Ann. Surg. Oncol. (2016) pmid: 26717940", "Include": "true"}, {"number": "48", "ReferenceId": "27958275", "FullCitation": "Williamson CT, et al. Nat Commun (2016) pmid: 27958275", "Include": "true"}, {"number": "49", "ReferenceId": "29252124", "FullCitation": "Thomas A, et al. J. Clin. Oncol. (2018) pmid: 29252124", "Include": "true"}, {"number": "50", "ReferenceId": "32568634", "FullCitation": "Yap TA, et al. J Clin Oncol (2020) pmid: 32568634", "Include": "true"}, {"number": "51", "ReferenceId": "25686104", "FullCitation": "Bitler BG, et al. Nat. Med. (2015) pmid: 25686104", "Include": "true"}, {"number": "52", "ReferenceId": "26552009", "FullCitation": "Kim KH, et al. Nat. Med. (2015) pmid: 26552009", "Include": "true"}, {"number": "53", "ReferenceId": "24559118", "FullCitation": "Wiegand KC, et al. BMC Cancer (2014) pmid: 24559118", "Include": "true"}, {"number": "54", "ReferenceId": "24336158", "FullCitation": "Huang HN, et al. Mod. Pathol. (2014) pmid: 24336158", "Include": "true"}, {"number": "55", "ReferenceId": "24979463", "FullCitation": "Samartzis EP, et al. Oncotarget (2014) pmid: 24979463", "Include": "true"}, {"number": "56", "ReferenceId": "24459582", "FullCitation": "Yokoyama Y, et al. J Gynecol Oncol (2014) pmid: 24459582", "Include": "true"}, {"number": "57", "ReferenceId": "24833095", "FullCitation": "Xie C, et al. Tumour Biol. (2014) pmid: 24833095", "Include": "true"}, {"number": "58", "ReferenceId": "21993244", "FullCitation": "Pylayeva_Gupta Y, et al. Nat. Rev. Cancer (2011) pmid: 21993244", "Include": "true"}, {"number": "59", "ReferenceId": "3310850", "FullCitation": "Kahn S, et al. Anticancer Res. () pmid: 3310850", "Include": "true"}, {"number": "60", "ReferenceId": "17150185", "FullCitation": "Akagi K, et al. Biochem. Biophys. Res. Commun. (2007) pmid: 17150185", "Include": "true"}, {"number": "61", "ReferenceId": "8955068", "FullCitation": "Bollag G, et al. J. Biol. Chem. (1996) pmid: 8955068", "Include": "true"}, {"number": "62", "ReferenceId": "20194776", "FullCitation": "Buhrman G, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20194776", "Include": "true"}, {"number": "63", "ReferenceId": "15367757", "FullCitation": "Sci. STKE (2004) pmid: 15367757", "Include": "true"}, {"number": "64", "ReferenceId": "16969076", "FullCitation": "Edkins S, et al. Cancer Biol. Ther. (2006) pmid: 16969076", "Include": "true"}, {"number": "65", "ReferenceId": "3043178", "FullCitation": "Feig LA, et al. Mol. Cell. Biol. (1988) pmid: 3043178", "Include": "true"}, {"number": "66", "ReferenceId": "20949621", "FullCitation": "Gremer L, et al. Hum. Mutat. (2011) pmid: 20949621", "Include": "true"}, {"number": "67", "ReferenceId": "20570890", "FullCitation": "Janakiraman M, et al. Cancer Res. (2010) pmid: 20570890", "Include": "true"}, {"number": "68", "ReferenceId": "27147599", "FullCitation": "Kim E, et al. Cancer Discov (2016) pmid: 27147599", "Include": "true"}, {"number": "69", "ReferenceId": "20838576", "FullCitation": "Lukman S, et al. PLoS Comput. Biol. (2010) pmid: 20838576", "Include": "true"}, {"number": "70", "ReferenceId": "21371307", "FullCitation": "Naguib A, et al. J Mol Signal (2011) pmid: 21371307", "Include": "true"}, {"number": "71", "ReferenceId": "22589270", "FullCitation": "Prior IA, et al. Cancer Res. (2012) pmid: 22589270", "Include": "true"}, {"number": "72", "ReferenceId": "1565661", "FullCitation": "Priv\u00e9 GG, et al. Proc. Natl. Acad. Sci. U.S.A. (1992) pmid: 1565661", "Include": "true"}, {"number": "73", "ReferenceId": "9219684", "FullCitation": "Scheffzek K, et al. Science (1997) pmid: 9219684", "Include": "true"}, {"number": "74", "ReferenceId": "19490892", "FullCitation": "Scholl C, et al. Cell (2009) pmid: 19490892", "Include": "true"}, {"number": "75", "ReferenceId": "20147967", "FullCitation": "Smith G, et al. Br. J. Cancer (2010) pmid: 20147967", "Include": "true"}, {"number": "76", "ReferenceId": "19075190", "FullCitation": "Tyner JW, et al. Blood (2009) pmid: 19075190", "Include": "true"}, {"number": "77", "ReferenceId": "2029511", "FullCitation": "Valencia A, et al. Biochemistry (1991) pmid: 2029511", "Include": "true"}, {"number": "78", "ReferenceId": "26854029", "FullCitation": "White Y, et al. Nat Commun (2016) pmid: 26854029", "Include": "true"}, {"number": "79", "ReferenceId": "8058307", "FullCitation": "Wiest JS, et al. Oncogene (1994) pmid: 8058307", "Include": "true"}, {"number": "80", "ReferenceId": "31289513", "FullCitation": "Angeles AKJ, et al. Oncol Lett (2019) pmid: 31289513", "Include": "true"}, {"number": "81", "ReferenceId": "24642870", "FullCitation": "Tong JH, et al. Cancer Biol. Ther. (2014) pmid: 24642870", "Include": "true"}, {"number": "82", "ReferenceId": "34117033", "FullCitation": "Loree JM, et al. Clin Cancer Res (2021) pmid: 34117033", "Include": "true"}, {"number": "83", "ReferenceId": "23103869", "FullCitation": "Biankin AV, et al. Nature (2012) pmid: 23103869", "Include": "true"}, {"number": "84", "ReferenceId": "25855536", "FullCitation": "Witkiewicz AK, et al. Nat Commun (2015) pmid: 25855536", "Include": "true"}, {"number": "85", "ReferenceId": "17520196", "FullCitation": "Feldmann G, et al. J Hepatobiliary Pancreat Surg (2007) pmid: 17520196", "Include": "true"}, {"number": "86", "ReferenceId": "23565280", "FullCitation": "Rachakonda PS, et al. PLoS ONE (2013) pmid: 23565280", "Include": "true"}, {"number": "87", "ReferenceId": "8342602", "FullCitation": "Hruban RH, et al. Am. J. Pathol. (1993) pmid: 8342602", "Include": "true"}, {"number": "88", "ReferenceId": "16549325", "FullCitation": "Maitra A, et al. Best Pract Res Clin Gastroenterol (2006) pmid: 16549325", "Include": "true"}, {"number": "89", "ReferenceId": "6320174", "FullCitation": "Nakano H, et al. Proc. Natl. Acad. Sci. U.S.A. (1984) pmid: 6320174", "Include": "true"}, {"number": "90", "ReferenceId": "21523318", "FullCitation": "Yamaguchi T, et al. Int. J. Oncol. (2011) pmid: 21523318", "Include": "true"}, {"number": "91", "ReferenceId": "23438367", "FullCitation": "Watanabe M, et al. Cancer Sci. (2013) pmid: 23438367", "Include": "true"}, {"number": "92", "ReferenceId": "21245089", "FullCitation": "Gilmartin AG, et al. Clin. Cancer Res. (2011) pmid: 21245089", "Include": "true"}, {"number": "93", "ReferenceId": "19372556", "FullCitation": "Yeh JJ, et al. Mol. Cancer Ther. (2009) pmid: 19372556", "Include": "true"}, {"number": "94", "ReferenceId": "35240087", "FullCitation": "Zhu X, et al. Lancet Oncol (2022) pmid: 35240087", "Include": "true"}, {"number": "95", "ReferenceId": "30833748", "FullCitation": "Kinsey CG, et al. Nat. Med. (2019) pmid: 30833748", "Include": "true"}, {"number": "96", "ReferenceId": "30833752", "FullCitation": "Bryant KL, et al. Nat. Med. (2019) pmid: 30833752", "Include": "true"}, {"number": "97", "ReferenceId": "29799479", "FullCitation": "Mahalingam D, et al. Cancers (Basel) (2018) pmid: 29799479", "Include": "true"}, {"number": "98", "ReferenceId": "31694832", "FullCitation": "Mahalingam D, et al. Clin. Cancer Res. (2019) pmid: 31694832", "Include": "true"}, {"number": "99", "ReferenceId": "27039845", "FullCitation": "Noonan AM, et al. Mol. Ther. (2016) pmid: 27039845", "Include": "true"}, {"number": "100", "ReferenceId": "26251290", "FullCitation": "Ko AH, et al. Clin. Cancer Res. (2016) pmid: 26251290", "Include": "true"}, {"number": "101", "ReferenceId": "27978579", "FullCitation": "Chung V, et al. JAMA Oncol (2017) pmid: 27978579", "Include": "true"}, {"number": "102", "ReferenceId": "25500057", "FullCitation": "Bedard PL, et al. Clin. Cancer Res. (2015) pmid: 25500057", "Include": "true"}, {"number": "103", "ReferenceId": "27975152", "FullCitation": "Van Laethem JL, et al. Target Oncol (2017) pmid: 27975152", "Include": "true"}, {"number": "104", "ReferenceId": "23583440", "FullCitation": "Infante JR, et al. Eur. J. Cancer (2013) pmid: 23583440", "Include": "true"}, {"number": "105", "ReferenceId": "24915778", "FullCitation": "Infante JR, et al. Eur. J. Cancer (2014) pmid: 24915778", "Include": "true"}, {"number": "106", "ReferenceId": "29756206", "FullCitation": "Van Cutsem E, et al. Int. J. Cancer (2018) pmid: 29756206", "Include": "true"}, {"number": "107", "ReferenceId": "21594619", "FullCitation": "Bodoky G, et al. Invest New Drugs (2012) pmid: 21594619", "Include": "true"}, {"number": "108", "ReferenceId": "15483017", "FullCitation": "Rinehart J, et al. J. Clin. Oncol. (2004) pmid: 15483017", "Include": "true"}, {"number": "109", "ReferenceId": "16009947", "FullCitation": "Lorusso PM, et al. J. Clin. Oncol. (2005) pmid: 16009947", "Include": "true"}, {"number": "110", "ReferenceId": "22805291", "FullCitation": "Infante JR, et al. Lancet Oncol. (2012) pmid: 22805291", "Include": "true"}, {"number": "111", "ReferenceId": "23434733", "FullCitation": "Weekes CD, et al. Clin. Cancer Res. (2013) pmid: 23434733", "Include": "true"}, {"number": "112", "ReferenceId": "25897431", "FullCitation": "Garrido_Laguna I, et al. Oncoscience (2015) pmid: 25897431", "Include": "true"}, {"number": "113", "ReferenceId": "33128873", "FullCitation": "Guo C, et al. Lancet Oncol (2020) pmid: 33128873", "Include": "true"}, {"number": "114", "ReferenceId": "31068384", "FullCitation": "Lu H, et al. Mol Cancer Ther (2019) pmid: 31068384", "Include": "true"}, {"number": "115", "ReferenceId": "29808006", "FullCitation": "Mainardi S, et al. Nat Med (2018) pmid: 29808006", "Include": "true"}, {"number": "116", "ReferenceId": "32816843", "FullCitation": "Hofmann MH, et al. Cancer Discov (2021) pmid: 32816843", "Include": "true"}, {"number": "117", "ReferenceId": "36173339", "FullCitation": "He H, et al. J Med Chem (2022) pmid: 36173339", "Include": "true"}, {"number": "118", "ReferenceId": "36384290", "FullCitation": "Zhang S, et al. J Med Chem (2022) pmid: 36384290", "Include": "true"}, {"number": "119", "ReferenceId": "36793426", "FullCitation": "Liu M, et al. ACS Med Chem Lett (2023) pmid: 36793426", "Include": "true"}, {"number": "120", "ReferenceId": "33719426", "FullCitation": "Ramharter J, et al. J Med Chem (2021) pmid: 33719426", "Include": "true"}, {"number": "121", "ReferenceId": "35833726", "FullCitation": "Ketcham JM, et al. J Med Chem (2022) pmid: 35833726", "Include": "true"}, {"number": "122", "ReferenceId": "36048281", "FullCitation": "Plangger A, et al. Discov Oncol (2022) pmid: 36048281", "Include": "true"}, {"number": "123", "ReferenceId": "36139627", "FullCitation": "Ma Y, et al. Cancers (Basel) (2022) pmid: 36139627", "Include": "true"}, {"number": "124", "ReferenceId": "12181402", "FullCitation": "Apperley JF, et al. N. Engl. J. Med. (2002) pmid: 12181402", "Include": "true"}, {"number": "125", "ReferenceId": "22897847", "FullCitation": "Roberts KG, et al. Cancer Cell (2012) pmid: 22897847", "Include": "true"}, {"number": "126", "ReferenceId": "21938754", "FullCitation": "Chmielecki J, et al. Genes Chromosomes Cancer (2012) pmid: 21938754", "Include": "true"}, {"number": "127", "ReferenceId": "15087377", "FullCitation": "Vizmanos JL, et al. Cancer Res. (2004) pmid: 15087377", "Include": "true"}, {"number": "128", "ReferenceId": "24628626", "FullCitation": "Kobayashi K, et al. Br. J. Haematol. (2014) pmid: 24628626", "Include": "true"}, {"number": "129", "ReferenceId": "14695158", "FullCitation": "Hwang RF, et al. Clin. Cancer Res. (2003) pmid: 14695158", "Include": "true"}, {"number": "130", "ReferenceId": "24725405", "FullCitation": "Weissmueller S, et al. Cell (2014) pmid: 24725405", "Include": "true"}, {"number": "131", "ReferenceId": "26940582", "FullCitation": "Kurahara H, et al. World J Surg (2016) pmid: 26940582", "Include": "true"}, {"number": "132", "ReferenceId": "24086736", "FullCitation": "Dornbusch J, et al. PLoS ONE (2013) pmid: 24086736", "Include": "true"}, {"number": "133", "ReferenceId": "23788753", "FullCitation": "Garcia_Donas J, et al. Ann. Oncol. (2013) pmid: 23788753", "Include": "true"}, {"number": "134", "ReferenceId": "27488093", "FullCitation": "Ma X, et al. Sci Rep (2016) pmid: 27488093", "Include": "true"}, {"number": "135", "ReferenceId": "20457621", "FullCitation": "Stacchiotti S, et al. Mol. Cancer Ther. (2010) pmid: 20457621", "Include": "true"}, {"number": "136", "ReferenceId": "22711763", "FullCitation": "Stacchiotti S, et al. Ann. Oncol. (2012) pmid: 22711763", "Include": "true"}, {"number": "137", "ReferenceId": "23542751", "FullCitation": "Shah CH, et al. Anticancer Drugs (2013) pmid: 23542751", "Include": "true"}, {"number": "138", "ReferenceId": "20093352", "FullCitation": "Stacchiotti S, et al. Ann. Oncol. (2010) pmid: 20093352", "Include": "true"}, {"number": "139", "ReferenceId": "28725989", "FullCitation": "Jawhar M, et al. Ann. Hematol. (2017) pmid: 28725989", "Include": "true"}, {"number": "140", "ReferenceId": "28010895", "FullCitation": "Appiah_Kubi K, et al. Crit. Rev. Oncol. Hematol. (2017) pmid: 28010895", "Include": "true"}, {"number": "141", "ReferenceId": "25400122", "FullCitation": "Kobayashi K, et al. Pediatr Blood Cancer (2015) pmid: 25400122", "Include": "true"}, {"number": "142", "ReferenceId": "24186319", "FullCitation": "Lengline E, et al. Haematologica (2013) pmid: 24186319", "Include": "true"}, {"number": "143", "ReferenceId": "25207766", "FullCitation": "Roberts KG, et al. N. Engl. J. Med. (2014) pmid: 25207766", "Include": "true"}, {"number": "144", "ReferenceId": "23835704", "FullCitation": "Weston BW, et al. J. Clin. Oncol. (2013) pmid: 23835704", "Include": "true"}, {"number": "145", "ReferenceId": "21072821", "FullCitation": "Li Z, et al. Pediatr Blood Cancer (2011) pmid: 21072821", "Include": "true"}, {"number": "146", "ReferenceId": "18950453", "FullCitation": "Metzgeroth G, et al. Br. J. Haematol. (2008) pmid: 18950453", "Include": "true"}, {"number": "147", "ReferenceId": "22331939", "FullCitation": "Cornfield D, et al. J. Clin. Oncol. (2012) pmid: 22331939", "Include": "true"}, {"number": "148", "ReferenceId": "16960151", "FullCitation": "David M, et al. Blood (2007) pmid: 16960151", "Include": "true"}, {"number": "149", "ReferenceId": "17296564", "FullCitation": "Walz C, et al. Haematologica (2007) pmid: 17296564", "Include": "true"}, {"number": "150", "ReferenceId": "23186533", "FullCitation": "Winkelmann N, et al. Leuk. Lymphoma (2013) pmid: 23186533", "Include": "true"}, {"number": "151", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "152", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "153", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "154", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "155", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "156", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "157", "ReferenceId": "29367431", "FullCitation": "Hu ZI, et al. Clin. Cancer Res. (2018) pmid: 29367431", "Include": "true"}, {"number": "158", "ReferenceId": "29056344", "FullCitation": "Campbell BB, et al. Cell (2017) pmid: 29056344", "Include": "true"}, {"number": "159", "ReferenceId": "29329208", "FullCitation": "Pihlak R, et al. Cancers (Basel) (2018) pmid: 29329208", "Include": "true"}, {"number": "160", "ReferenceId": "29523759", "FullCitation": "Salem ME, et al. Mol. Cancer Res. (2018) pmid: 29523759", "Include": "true"}, {"number": "161", "ReferenceId": "23029359", "FullCitation": "Laghi L, et al. PLoS ONE (2012) pmid: 23029359", "Include": "true"}, {"number": "162", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "163", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "164", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "165", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "166", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "167", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "168", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "169", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "170", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "171", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "172", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "173", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "174", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "175", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "176", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "177", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "178", "ReferenceId": "32919526", "FullCitation": "Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526", "Include": "true"}, {"number": "179", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "180", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "181", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "182", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "183", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "184", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "185", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "186", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "187", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "188", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "189", "ReferenceId": "30557521", "FullCitation": "Ott PA, et al. J. Clin. Oncol. (2019) pmid: 30557521", "Include": "true"}, {"number": "190", "ReferenceId": "35101941", "FullCitation": "Cristescu R, et al. J Immunother Cancer (2022) pmid: 35101941", "Include": "true"}, {"number": "191", "ReferenceId": "34876409", "FullCitation": "Friedman CF, et al. Cancer Discov (2022) pmid: 34876409", "Include": "true"}, {"number": "192", "ReferenceId": "35274716", "FullCitation": "Sturgill EG, et al. Oncologist (2022) pmid: 35274716", "Include": "true"}, {"number": "193", "ReferenceId": "19935675", "FullCitation": "Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675", "Include": "true"}, {"number": "194", "ReferenceId": "18410249", "FullCitation": "Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249", "Include": "true"}, {"number": "195", "ReferenceId": "12826609", "FullCitation": "Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609", "Include": "true"}, {"number": "196", "ReferenceId": "20978130", "FullCitation": "Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130", "Include": "true"}, {"number": "197", "ReferenceId": "28472496", "FullCitation": "Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496", "Include": "true"}, {"number": "198", "ReferenceId": "17690113", "FullCitation": "Yamada H, et al. Carcinogenesis (2007) pmid: 17690113", "Include": "true"}, {"number": "199", "ReferenceId": "20018721", "FullCitation": "Morton JP, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20018721", "Include": "true"}, {"number": "200", "ReferenceId": "8494051", "FullCitation": "Scarpa A, et al. Am. J. Pathol. (1993) pmid: 8494051", "Include": "true"}, {"number": "201", "ReferenceId": "22782330", "FullCitation": "Luo Y, et al. Pathol. Oncol. Res. (2013) pmid: 22782330", "Include": "true"}, {"number": "202", "ReferenceId": "22896692", "FullCitation": "Iacobuzio_Donahue CA, et al. Clin. Cancer Res. (2012) pmid: 22896692", "Include": "true"}, {"number": "203", "ReferenceId": "22806689", "FullCitation": "Macgregor_Das AM, et al. J Surg Oncol (2013) pmid: 22806689", "Include": "true"}, {"number": "204", "ReferenceId": "23470568", "FullCitation": "Oshima M, et al. Ann. Surg. (2013) pmid: 23470568", "Include": "true"}, {"number": "205", "ReferenceId": "22351431", "FullCitation": "Ottenhof NA, et al. Cell Oncol (Dordr) (2012) pmid: 22351431", "Include": "true"}, {"number": "206", "ReferenceId": "20414934", "FullCitation": "Tsiambas E, et al. J BUON () pmid: 20414934", "Include": "true"}, {"number": "207", "ReferenceId": "21644238", "FullCitation": "Ansari D, et al. Br J Surg (2011) pmid: 21644238", "Include": "true"}, {"number": "208", "ReferenceId": "21404460", "FullCitation": "Grochola LF, et al. Pancreas (2011) pmid: 21404460", "Include": "true"}, {"number": "209", "ReferenceId": "20107315", "FullCitation": "Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315", "Include": "true"}, {"number": "210", "ReferenceId": "21799033", "FullCitation": "Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033", "Include": "true"}, {"number": "211", "ReferenceId": "21389100", "FullCitation": "Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100", "Include": "true"}, {"number": "212", "ReferenceId": "25504633", "FullCitation": "Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633", "Include": "true"}, {"number": "213", "ReferenceId": "12489850", "FullCitation": "Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850", "Include": "true"}, {"number": "214", "ReferenceId": "11713371", "FullCitation": "Xu L, et al. Mol. Med. (2001) pmid: 11713371", "Include": "true"}, {"number": "215", "ReferenceId": "23470564", "FullCitation": "Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564", "Include": "true"}, {"number": "216", "ReferenceId": "25240597", "FullCitation": "Kim SS, et al. Nanomedicine (2015) pmid: 25240597", "Include": "true"}, {"number": "217", "ReferenceId": "27357628", "FullCitation": "Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628", "Include": "true"}, {"number": "218", "ReferenceId": "27601554", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554", "Include": "true"}, {"number": "219", "ReferenceId": "27998224", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224", "Include": "true"}, {"number": "220", "ReferenceId": "31315834", "FullCitation": "Lee J, et al. Cancer Discov (2019) pmid: 31315834", "Include": "true"}, {"number": "221", "ReferenceId": "29535125", "FullCitation": "M\u00e9ndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125", "Include": "true"}, {"number": "222", "ReferenceId": "34538072", "FullCitation": "Seligmann JF, et al. J Clin Oncol (2021) pmid: 34538072", "Include": "true"}, {"number": "223", "ReferenceId": "36084396", "FullCitation": "Park H, et al. ESMO Open (2022) pmid: 36084396", "Include": "true"}, {"number": "224", "ReferenceId": "29165669", "FullCitation": "Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669", "Include": "true"}, {"number": "225", "ReferenceId": "26014290", "FullCitation": "Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290", "Include": "true"}, {"number": "226", "ReferenceId": "23355100", "FullCitation": "Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100", "Include": "true"}, {"number": "227", "ReferenceId": "11219776", "FullCitation": "Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776", "Include": "true"}, {"number": "228", "ReferenceId": "9006316", "FullCitation": "Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316", "Include": "true"}, {"number": "229", "ReferenceId": "19204208", "FullCitation": "Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208", "Include": "true"}, {"number": "230", "ReferenceId": "12672316", "FullCitation": "Lalloo F, et al. Lancet (2003) pmid: 12672316", "Include": "true"}, {"number": "231", "ReferenceId": "31050713", "FullCitation": "Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713", "Include": "true"}, {"number": "232", "ReferenceId": "25426837", "FullCitation": "Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837", "Include": "true"}, {"number": "233", "ReferenceId": "25426838", "FullCitation": "Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838", "Include": "true"}, {"number": "234", "ReferenceId": "25326804", "FullCitation": "Xie M, et al. Nat. Med. (2014) pmid: 25326804", "Include": "true"}, {"number": "235", "ReferenceId": "28669404", "FullCitation": "Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404", "Include": "true"}, {"number": "236", "ReferenceId": "29678827", "FullCitation": "Severson EA, et al. Blood (2018) pmid: 29678827", "Include": "true"}, {"number": "237", "ReferenceId": "29420212", "FullCitation": "Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212", "Include": "true"}, {"number": "238", "ReferenceId": "30504320", "FullCitation": "Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320", "Include": "true"}, {"number": "239", "ReferenceId": "32269342", "FullCitation": "Chabon JJ, et al. Nature (2020) pmid: 32269342", "Include": "true"}, {"number": "240", "ReferenceId": "31768066", "FullCitation": "Razavi P, et al. Nat. Med. (2019) pmid: 31768066", "Include": "true"}, {"number": "241", "ReferenceId": "8521522", "FullCitation": "Quelle DE, et al. Cell (1995) pmid: 8521522", "Include": "true"}, {"number": "242", "ReferenceId": "15878778", "FullCitation": "Mutat. Res. (2005) pmid: 15878778", "Include": "true"}, {"number": "243", "ReferenceId": "9484839", "FullCitation": "Gazzeri S, et al. Oncogene (1998) pmid: 9484839", "Include": "true"}, {"number": "244", "ReferenceId": "10498883", "FullCitation": "Oncogene (1999) pmid: 10498883", "Include": "true"}, {"number": "245", "ReferenceId": "16869746", "FullCitation": "Sherr CJ, et al. Cold Spring Harb. Symp. Quant. Biol. (2005) pmid: 16869746", "Include": "true"}, {"number": "246", "ReferenceId": "20549699", "FullCitation": "Ozenne P, et al. Int. J. Cancer (2010) pmid: 20549699", "Include": "true"}, {"number": "247", "ReferenceId": "10498896", "FullCitation": "Ruas M, et al. Oncogene (1999) pmid: 10498896", "Include": "true"}, {"number": "248", "ReferenceId": "17909018", "FullCitation": "Jones R, et al. Cancer Res. (2007) pmid: 17909018", "Include": "true"}, {"number": "249", "ReferenceId": "18843795", "FullCitation": "Haferkamp S, et al. Aging Cell (2008) pmid: 18843795", "Include": "true"}, {"number": "250", "ReferenceId": "12417717", "FullCitation": "Huot TJ, et al. Mol. Cell. Biol. (2002) pmid: 12417717", "Include": "true"}, {"number": "251", "ReferenceId": "11518711", "FullCitation": "Rizos H, et al. J. Biol. Chem. (2001) pmid: 11518711", "Include": "true"}, {"number": "252", "ReferenceId": "9324288", "FullCitation": "Gombart AF, et al. Leukemia (1997) pmid: 9324288", "Include": "true"}, {"number": "253", "ReferenceId": "7780957", "FullCitation": "Yang R, et al. Cancer Res. (1995) pmid: 7780957", "Include": "true"}, {"number": "254", "ReferenceId": "8668202", "FullCitation": "Parry D, et al. Mol. Cell. Biol. (1996) pmid: 8668202", "Include": "true"}, {"number": "255", "ReferenceId": "12606942", "FullCitation": "Greenblatt MS, et al. Oncogene (2003) pmid: 12606942", "Include": "true"}, {"number": "256", "ReferenceId": "10491434", "FullCitation": "Yarbrough WG, et al. J. Natl. Cancer Inst. (1999) pmid: 10491434", "Include": "true"}, {"number": "257", "ReferenceId": "11255261", "FullCitation": "Poi MJ, et al. Mol. Carcinog. (2001) pmid: 11255261", "Include": "true"}, {"number": "258", "ReferenceId": "9660926", "FullCitation": "Byeon IJ, et al. Mol. Cell (1998) pmid: 9660926", "Include": "true"}, {"number": "259", "ReferenceId": "19260062", "FullCitation": "Kannengiesser C, et al. Hum. Mutat. (2009) pmid: 19260062", "Include": "true"}, {"number": "260", "ReferenceId": "10719365", "FullCitation": "Lal G, et al. Genes Chromosomes Cancer (2000) pmid: 10719365", "Include": "true"}, {"number": "261", "ReferenceId": "7777061", "FullCitation": "Koh J, et al. Nature (1995) pmid: 7777061", "Include": "true"}, {"number": "262", "ReferenceId": "20340136", "FullCitation": "McKenzie HA, et al. Hum. Mutat. (2010) pmid: 20340136", "Include": "true"}, {"number": "263", "ReferenceId": "21462282", "FullCitation": "Miller PJ, et al. Hum. Mutat. (2011) pmid: 21462282", "Include": "true"}, {"number": "264", "ReferenceId": "905385", "FullCitation": "Kutscher CL, et al. Physiol. Behav. (1977) pmid: 905385", "Include": "true"}, {"number": "265", "ReferenceId": "24659262", "FullCitation": "Scaini MC, et al. Hum. Mutat. (2014) pmid: 24659262", "Include": "true"}, {"number": "266", "ReferenceId": "23190892", "FullCitation": "Jenkins NC, et al. J. Invest. Dermatol. (2013) pmid: 23190892", "Include": "true"}, {"number": "267", "ReferenceId": "10389768", "FullCitation": "Walker GJ, et al. Int. J. Cancer (1999) pmid: 10389768", "Include": "true"}, {"number": "268", "ReferenceId": "12853981", "FullCitation": "Rutter JL, et al. Oncogene (2003) pmid: 12853981", "Include": "true"}, {"number": "269", "ReferenceId": "18538737", "FullCitation": "Itahana K, et al. Cancer Cell (2008) pmid: 18538737", "Include": "true"}, {"number": "270", "ReferenceId": "10360174", "FullCitation": "Zhang Y, et al. Mol. Cell (1999) pmid: 10360174", "Include": "true"}, {"number": "271", "ReferenceId": "9529249", "FullCitation": "Zhang Y, et al. Cell (1998) pmid: 9529249", "Include": "true"}, {"number": "272", "ReferenceId": "25873077", "FullCitation": "Jafri M, et al. Cancer Discov (2015) pmid: 25873077", "Include": "true"}, {"number": "273", "ReferenceId": "17600882", "FullCitation": "Tsiambas E, et al. J BUON () pmid: 17600882", "Include": "true"}, {"number": "274", "ReferenceId": "16497872", "FullCitation": "Bergmann F, et al. J. Clin. Pathol. (2006) pmid: 16497872", "Include": "true"}, {"number": "275", "ReferenceId": "15985168", "FullCitation": "Attri J, et al. BMC Gastroenterol (2005) pmid: 15985168", "Include": "true"}, {"number": "276", "ReferenceId": "11161385", "FullCitation": "Moore PS, et al. Br. J. Cancer (2001) pmid: 11161385", "Include": "true"}, {"number": "277", "ReferenceId": "12610506", "FullCitation": "Klump B, et al. Br. J. Cancer (2003) pmid: 12610506", "Include": "true"}, {"number": "278", "ReferenceId": "11706079", "FullCitation": "Geradts J, et al. Mod. Pathol. (2001) pmid: 11706079", "Include": "true"}, {"number": "279", "ReferenceId": "20665497", "FullCitation": "Chang DT, et al. Cancer (2010) pmid: 20665497", "Include": "true"}, {"number": "280", "ReferenceId": "21278246", "FullCitation": "Konecny GE, et al. Clin. Cancer Res. (2011) pmid: 21278246", "Include": "true"}, {"number": "281", "ReferenceId": "21871868", "FullCitation": "Katsumi Y, et al. Biochem. Biophys. Res. Commun. (2011) pmid: 21871868", "Include": "true"}, {"number": "282", "ReferenceId": "22711607", "FullCitation": "Cen L, et al. Neuro_oncology (2012) pmid: 22711607", "Include": "true"}, {"number": "283", "ReferenceId": "23898052", "FullCitation": "Logan JE, et al. Anticancer Res. (2013) pmid: 23898052", "Include": "true"}, {"number": "284", "ReferenceId": "35157829", "FullCitation": "Fennell DA, et al. Lancet Oncol (2022) pmid: 35157829", "Include": "true"}, {"number": "285", "ReferenceId": "28283584", "FullCitation": "Elvin JA, et al. Oncologist (2017) pmid: 28283584", "Include": "true"}, {"number": "286", "ReferenceId": "26715889", "FullCitation": "Gao J, et al. Curr Oncol (2015) pmid: 26715889", "Include": "true"}, {"number": "287", "ReferenceId": "25501126", "FullCitation": "DeMichele A, et al. Clin. Cancer Res. (2015) pmid: 25501126", "Include": "true"}, {"number": "288", "ReferenceId": "25524798", "FullCitation": "Finn RS, et al. Lancet Oncol. (2015) pmid: 25524798", "Include": "true"}, {"number": "289", "ReferenceId": "27542767", "FullCitation": "Infante JR, et al. Clin. Cancer Res. (2016) pmid: 27542767", "Include": "true"}, {"number": "290", "ReferenceId": "24797823", "FullCitation": "Johnson DB, et al. Oncologist (2014) pmid: 24797823", "Include": "true"}, {"number": "291", "ReferenceId": "22090362", "FullCitation": "Flaherty KT, et al. Clin. Cancer Res. (2012) pmid: 22090362", "Include": "true"}, {"number": "292", "ReferenceId": "23569312", "FullCitation": "Dickson MA, et al. J. Clin. Oncol. (2013) pmid: 23569312", "Include": "true"}, {"number": "293", "ReferenceId": "31700061", "FullCitation": "Su D, et al. Nat Commun (2019) pmid: 31700061", "Include": "true"}, {"number": "294", "ReferenceId": "32923894", "FullCitation": "Tramontana TF, et al. JCO Precis Oncol (2020) pmid: 32923894", "Include": "true"}, {"number": "295", "ReferenceId": "21460101", "FullCitation": "Van Maerken T, et al. Mol. Cancer Ther. (2011) pmid: 21460101", "Include": "true"}, {"number": "296", "ReferenceId": "21725357", "FullCitation": "Gamble LD, et al. Oncogene (2012) pmid: 21725357", "Include": "true"}, {"number": "297", "ReferenceId": "7666917", "FullCitation": "Whelan AJ, et al. N Engl J Med (1995) pmid: 7666917", "Include": "true"}, {"number": "298", "ReferenceId": "20687502", "FullCitation": "Adv Exp Med Biol (2010) pmid: 20687502", "Include": "true"}, {"number": "299", "ReferenceId": "9479083", "FullCitation": "Hogg D, et al. J Cutan Med Surg (1998) pmid: 9479083", "Include": "true"}, {"number": "300", "ReferenceId": "29543703", "FullCitation": "De Unamuno B, et al. Melanoma Res (2018) pmid: 29543703", "Include": "true"}, {"number": "301", "ReferenceId": "26892650", "FullCitation": "Soura E, et al. J Am Acad Dermatol (2016) pmid: 26892650", "Include": "true"}, {"number": "302", "ReferenceId": "29405243", "FullCitation": "Huerta C, et al. Acta Derm Venereol (2018) pmid: 29405243", "Include": "true"}, {"number": "303", "ReferenceId": "8414022", "FullCitation": "Kaufman DK, et al. Neurology (1993) pmid: 8414022", "Include": "true"}, {"number": "304", "ReferenceId": "9622062", "FullCitation": "Bahuau M, et al. Cancer Res (1998) pmid: 9622062", "Include": "true"}, {"number": "305", "ReferenceId": "28699883", "FullCitation": "Chan AK, et al. Clin Neuropathol () pmid: 28699883", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2023_05_09 15:23:30", "OpName": "Julie Tse, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Julie Tse, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "907x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "6 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "PANCREAS", "disease_ontology": "Pancreas ductal adenocarcinoma", "flowcell_analysis": "2000028974", "gender": "male", "pathology_diagnosis": "Adenocarcinoma", "percent_tumor_nuclei": "40", "pipeline_version": "v3.22.0", "purity_assessment": "26.58", "specimen": "ORD_1620416_01*US1546514.01", "study": "CLINICAL_F1CDx v2", "test_request": "ORD_1620416_01", "test_type": "FoundationOneDx", "tissue_of_origin": "Pancreas", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "DX2", "mean_exon_depth": "896.56", "name": "SQ_US1546514.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.2616", "cds_effect": "557A>G", "depth": "776", "equivocal": "false", "functional_effect": "missense", "gene": "MAP2K4", "percent_reads": "26.16", "position": "chr17:12011150", "protein_effect": "D186G", "status": "unknown", "strand": "+", "transcript": "NM_003010", "dna_evidence": {"sample": "SQ_US1546514.01_1"}}, {"allele_fraction": "0.4094", "cds_effect": "2470G>A", "depth": "679", "equivocal": "false", "functional_effect": "missense", "gene": "ABL1", "percent_reads": "40.94", "position": "chr9:133760147", "protein_effect": "V824M", "status": "unknown", "strand": "+", "transcript": "NM_005157", "dna_evidence": {"sample": "SQ_US1546514.01_1"}}, {"allele_fraction": "0.0836", "cds_effect": "101A>G", "depth": "1101", "equivocal": "false", "functional_effect": "missense", "gene": "PDGFRA", "percent_reads": "8.36", "position": "chr4:55127313", "protein_effect": "E34G", "status": "unknown", "strand": "+", "transcript": "NM_006206", "dna_evidence": {"sample": "SQ_US1546514.01_1"}}, {"allele_fraction": "0.0948", "cds_effect": "86_87insAGATATAGA", "depth": "812", "equivocal": "false", "functional_effect": "nonframeshift", "gene": "NFE2L2", "percent_reads": "9.48", "position": "chr2:178098958", "protein_effect": "I28_D29insEDI", "status": "unknown", "strand": "_", "transcript": "NM_006164", "dna_evidence": {"sample": "SQ_US1546514.01_1"}}, {"allele_fraction": "0.0855", "cds_effect": "1348G>T", "depth": "608", "equivocal": "false", "functional_effect": "nonsense", "gene": "CSF3R", "percent_reads": "8.55", "position": "chr1:36935379", "protein_effect": "E450*", "status": "unknown", "strand": "_", "transcript": "NM_156039", "dna_evidence": {"sample": "SQ_US1546514.01_1"}}, {"allele_fraction": "0.4136", "cds_effect": "1174G>C", "depth": "706", "equivocal": "false", "functional_effect": "missense", "gene": "SGK1", "percent_reads": "41.36", "position": "chr6:134491528", "protein_effect": "E392Q", "status": "unknown", "strand": "_", "transcript": "NM_005627", "dna_evidence": {"sample": "SQ_US1546514.01_1"}}, {"allele_fraction": "0.267", "cds_effect": "1024C>T", "depth": "663", "equivocal": "false", "functional_effect": "nonsense", "gene": "TP53", "percent_reads": "26.7", "position": "chr17:7574003", "protein_effect": "R342*", "status": "known", "strand": "_", "transcript": "NM_000546", "dna_evidence": {"sample": "SQ_US1546514.01_1"}}, {"allele_fraction": "0.9983", "cds_effect": "528C>A", "depth": "604", "equivocal": "false", "functional_effect": "missense", "gene": "AR", "percent_reads": "99.83", "position": "chrX:66765516", "protein_effect": "S176R", "status": "unknown", "strand": "+", "transcript": "NM_000044", "dna_evidence": {"sample": "SQ_US1546514.01_1"}}, {"allele_fraction": "0.2284", "cds_effect": "35G>T", "depth": "810", "equivocal": "false", "functional_effect": "missense", "gene": "KRAS", "percent_reads": "22.84", "position": "chr12:25398284", "protein_effect": "G12V", "status": "known", "strand": "_", "transcript": "NM_004985", "dna_evidence": {"sample": "SQ_US1546514.01_1"}}, {"allele_fraction": "0.5061", "cds_effect": "2467G>A", "depth": "816", "equivocal": "false", "functional_effect": "missense", "gene": "PDGFRB", "percent_reads": "50.61", "position": "chr5:149500570", "protein_effect": "V823I", "status": "known", "strand": "_", "transcript": "NM_002609", "dna_evidence": {"sample": "SQ_US1546514.01_1"}}, {"allele_fraction": "0.3845", "cds_effect": "6035A>T", "depth": "580", "equivocal": "false", "functional_effect": "missense", "gene": "ATRX", "percent_reads": "38.45", "position": "chrX:76849241", "protein_effect": "E2012V", "status": "unknown", "strand": "_", "transcript": "NM_000489", "dna_evidence": {"sample": "SQ_US1546514.01_1"}}, {"allele_fraction": "0.5714", "cds_effect": "131A>G", "depth": "861", "equivocal": "false", "functional_effect": "missense", "gene": "PTCH1", "percent_reads": "57.14", "position": "chr9:98278972", "protein_effect": "E44G", "status": "unknown", "strand": "_", "transcript": "NM_001083603", "dna_evidence": {"sample": "SQ_US1546514.01_1"}}, {"allele_fraction": "0.4036", "cds_effect": "1463G>A", "depth": "726", "equivocal": "false", "functional_effect": "missense", "gene": "ERBB3", "percent_reads": "40.36", "position": "chr12:56487317", "protein_effect": "R488Q", "status": "unknown", "strand": "+", "transcript": "NM_001982", "dna_evidence": {"sample": "SQ_US1546514.01_1"}}, {"allele_fraction": "0.0804", "cds_effect": "2009C>T", "depth": "547", "equivocal": "false", "functional_effect": "missense", "gene": "CARD11", "percent_reads": "8.04", "position": "chr7:2962899", "protein_effect": "T670M", "status": "unknown", "strand": "_", "transcript": "NM_032415", "dna_evidence": {"sample": "SQ_US1546514.01_1"}}, {"allele_fraction": "0.1304", "cds_effect": "1126delC", "depth": "69", "equivocal": "false", "functional_effect": "frameshift", "gene": "ARID1A", "percent_reads": "13.04", "position": "chr1:27024019", "protein_effect": "R376fs*15", "status": "likely", "strand": "+", "transcript": "NM_006015", "dna_evidence": {"sample": "SQ_US1546514.01_1"}}, {"allele_fraction": "0.4193", "cds_effect": "797T>C", "depth": "861", "equivocal": "false", "functional_effect": "missense", "gene": "FH", "percent_reads": "41.93", "position": "chr1:241669410", "protein_effect": "M266T", "status": "unknown", "strand": "_", "transcript": "NM_000143", "dna_evidence": {"sample": "SQ_US1546514.01_1"}}]}, "copy_number_alterations": {"copy_number_alteration": [{"copy_number": "0", "equivocal": "false", "gene": "CDKN2B", "number_of_exons": "5 of 5", "position": "chr9:22002170_22010784", "ratio": "0.72", "status": "known", "type": "loss", "dna_evidence": {"sample": "SQ_US1546514.01_1"}}, {"copy_number": "24", "equivocal": "false", "gene": "HSD3B1", "number_of_exons": "3 of 3", "position": "chr1:120050099_120057268", "ratio": "2.83", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1546514.01_1"}}, {"copy_number": "0", "equivocal": "false", "gene": "CDKN2A", "number_of_exons": "5 of 5", "position": "chr9:21968169_21994453", "ratio": "0.72", "status": "known", "type": "loss", "dna_evidence": {"sample": "SQ_US1546514.01_1"}}]}, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "6.03", "status": "intermediate", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}